Can ozanimod treat multiple sclerosis?

Multiple sclerosis (MS) is a complex disease of the central nervous system that can cause permanent disability in young people. Ozamod (ozanimod), an oral drug belonging to the sphingosine-1-phosphate receptor (S1PR) modulator family, has recently been approved in different countries for the treatment of multiple sclerosis with active disease. It selectively modulates S1PR1 and S1PR5 to prevent autoreactive lymphocytes from entering the central nervous system (CNS) where they can determine inflammation and neurodegeneration.

Ozamod was tested in one Phase II and two Phase III pivotal trials and was shown to be effective and well tolerated. The study showed that the risk of adverse reactions was significantly lower when taking ozanimod for the first time compared with taking fingolimod for the first time. Additionally, a lower risk of reduced heart rate, atrioventricular block, and conduction abnormalities was observed in patients treated with ozanimod. A lower risk of any adverse event was observed with ozanimod than with fingolimod after 1 and 2 years of treatment. No statistically significant differences were found in relapse rates and confirmed disability progression after 3 and 6 months of treatment.

The original drug Ozamod has been launched in China, but it has been on the market for a short time and has not been included in the medical insurance. The specific price is not yet clear, and domestic purchase channels are relatively difficult. The price of Ozamod original drug specifications0.92*28 capsules per box listed overseas may be around 19,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There is currently no generic version of Ozamod produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.